TNBCI3K: A Promising Drug Target for Neurodegenerative Disorders, Cancer and Autoimmune Diseases

Target Name: TNNI3K

NCBI ID: G51086

TNNI3K

TNBCI3K: A Promising Drug Target for Neurodegenerative Disorders, Cancer and Autoimmune Diseases

TNBCI3K (Triazactinyl-N-acetylated-L-histidine), also known as FPGT-TNNI3K, is a drug target and a biomarker that has been shown to play a crucial role in various diseases, including neurodegenerative disorders, cancer, and autoimmune diseases. Its unique structure and chemical properties make it an attractive target for drug development.

Structure and Properties

TNBCI3K is a small molecule that has a molecular weight of 113.15 g/mol. It is a triazactinyl compound, which means that it has a nitrogen atom that is bonded to a carbon atom that is also bonded to a second nitrogen atom. The nitrogen atom has a p-type charge, which makes it a good candidate for a drug target. Additionally, it has an acetyl group attached to the carbon atom, which can modulate its chemical properties and also enhance its pharmacological activity.

TNBCI3K has been shown to have a number of unique properties that make it an attractive drug target. Its triazactinyl structure allows it to have a long and flexible carbon chain, which can make it easier to reach and modulate. The nitrogen atom has a p-type charge, which makes it a good candidate for a drug target. The acetyl group also has been shown to enhance the drug's pharmacological activity by increasing its stability and improving its bioavailability.

Drug Development

TNBCI3K has been shown to be a potential drug target in various diseases. Its unique structure and properties make it an attractive candidate for targeting diseases that involve the regulation of the nitrogen cycle, such as neurodegenerative disorders, cancer, and autoimmune diseases.

In neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, the regulation of the nitrogen cycle is disrupted, leading to the accumulation of toxic protein aggregates that cause the symptoms of the disease. Targeting the nitrogen cycle by modulating the activity of TNNI3K may provide a new approach to treating these disorders.

In cancer, TNNI3K has been shown to be a potential drug target for modulating the regulation of the nitrogen cycle. Cancer cells have a high rate of protein synthesis, which requires the availability of nitrogen-containing compounds to synthesize new proteins. The regulation of the nitrogen cycle is a critical part of this process, and targeting the activity of TNNI3K may be a way to inhibit cancer cell growth.

In autoimmune diseases, such as rheumatoid arthritis and lupus, the immune system attacks the body's own tissues, leading to inflammation and damage. The regulation of the nitrogen cycle is a critical part of this process, and targeting the activity of TNNI3K may be a way to treat autoimmune diseases.

Conclusion

TNBCI3K is a drug target and a biomarker that has shown promise in treating a variety of diseases. Its unique structure and properties make it an attractive candidate for drug development. The regulation of the nitrogen cycle is a critical part of many diseases, and targeting the activity of TNNI3K may provide a new approach to treating these disorders. Further research is needed to fully understand the potential of TNNI3K as a drug target and biomarker.

Protein Name: TNNI3 Interacting Kinase

The "TNNI3K Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TNNI3K comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets